EAACI Congress 2025
BackL-TPS02 - Asthma 09
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D1.119
Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model
D1.130
Associations between Serum Clara Cell Protein 16 (CC16) and Asthma Severity in Children
D1.125
Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos
D1.129
Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD
D1.117
Combing dual biologics therapy for severe asthma : a series of ten cases
D1.126
Deciphering Genetic Causal Relationships and Molecular Mechanisms Linking Multiple Allergic Diseases and Schizophrenia
D1.127
Distinct roles of Natural killer T Cells and Innate Lymphoid Cells in Type I and II airway Inflammation Induced by Viral Infection
D1.128
Dupilumab in a Child with Severe Allergic Asthma, Atopic Dermatitis, Vernal Keratoconjunctivitis, and Partial IgA Deficiency
D1.122
Hydrogen peroxide in exhaled breath condensate as a marker for monitoring biologic treatment response in severe asthmatic patients
D1.123
Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment
D1.124
Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab
D1.116
Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis
D1.131
TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)
D1.118
The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience
